Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211900 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Manufacturing Lot of StaphVAX
A Phase 3 study, sponsored by Nabi Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 65
- Enrollment target
NCT00211900 is a Phase 3 study that has completed, run by Nabi Biopharmaceuticals. The registered enrollment target is 65 participants.
The verdict
NCT00211900, a Phase 3 study, has completed, sponsored by Nabi Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 65 participants
- Enrollment target
Study Summary
This study answers a U.S. Food and Drug Administration requirement for evaluation in people of a manufacturing lot of vaccine. Subjects receive one dose of one lot of vaccine. The antibodies in the blood measure the immunogenicity of the vaccine, and typical vaccine safety information is also collected.
Interventions
- BIOLOGICAL S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2005-03 |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00211900
The ClinicalTrials.gov registry entry for NCT00211900 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nabi Biopharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine is the first listed.
NCT00211900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00211900 about?
NCT00211900 is a clinical study titled "Evaluation of Manufacturing Lot of StaphVAX". This study answers a U.S. Food and Drug Administration requirement for evaluation in people of a manufacturing lot of vaccine. Subjects receive one dose of one lot of vaccine. The antibodies in the blood measure the immunogenicity of the vaccine, and typical vaccine safety information is also collec...
What is the current status of trial NCT00211900?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 65 participants. The study started on 2005-03. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00211900?
The interventions under investigation include: S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00211900?
This trial is sponsored by Nabi Biopharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.